Every year there are approximately 140,000 newly diagnosed colorectal cancer cases in the United States. Following primary treatment, 30-50% of patients will see their cancer return, most of which will be within the first 2 – 3 years. (1)
Early detection of recurrent colorectal cancer may allow for additional treatment options and improved patient care.
COLVERA® detects two methylated (silenced) genes, BCAT1 and IKZF1, associated with colorectal tumor growth in circulating tumor DNA, a technology that has greater sensitivity for colorectal cancer than measuring for CEA, the current standard of care.
In recent studies, COLVERA® detected twice the number of recurrent cases compared to CEA and can detect colorectal cancer recurrence up to 5 months earlier than CEA with a positive predictive value of 94%. (2, 3)
COLVERA® is a Laboratory Developed Test supplied by Clinical Genomics Pathology Inc. a CLIA Certified, CAP-accredited laboratory in Bridgewater, NJ, USA.
(2) Graeme P. Young, Susanne K. Pedersen, et al. A cross‐sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor‐derived DNA with CEA for detection of recurrent colorectal cancer. Cancer Medicine. 2016; 5 (10): 2763–2772.